...
首页> 外文期刊>PLoS Computational Biology >Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan
【24h】

Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan

机译:与已知序列的任何HLA-DR分子结合的肽的定量预测:NetMHCIIpan

获取原文
   

获取外文期刊封面封底 >>

       

摘要

CD4 positive T helper cells control many aspects of specific immunity. These cells are specific for peptides derived from protein antigens and presented by molecules of the extremely polymorphic major histocompatibility complex (MHC) class II system. The identification of peptides that bind to MHC class II molecules is therefore of pivotal importance for rational discovery of immune epitopes. HLA-DR is a prominent example of a human MHC class II. Here, we present a method, NetMHCIIpan, that allows for pan-specific predictions of peptide binding to any HLA-DR molecule of known sequence. The method is derived from a large compilation of quantitative HLA-DR binding events covering 14 of the more than 500 known HLA-DR alleles. Taking both peptide and HLA sequence information into account, the method can generalize and predict peptide binding also for HLA-DR molecules where experimental data is absent. Validation of the method includes identification of endogenously derived HLA class II ligands, cross-validation, leave-one-molecule-out, and binding motif identification for hitherto uncharacterized HLA-DR molecules. The validation shows that the method can successfully predict binding for HLA-DR molecules—even in the absence of specific data for the particular molecule in question. Moreover, when compared to TEPITOPE, currently the only other publicly available prediction method aiming at providing broad HLA-DR allelic coverage, NetMHCIIpan performs equivalently for alleles included in the training of TEPITOPE while outperforming TEPITOPE on novel alleles. We propose that the method can be used to identify those hitherto uncharacterized alleles, which should be addressed experimentally in future updates of the method to cover the polymorphism of HLA-DR most efficiently. We thus conclude that the presented method meets the challenge of keeping up with the MHC polymorphism discovery rate and that it can be used to sample the MHC “space,” enabling a highly efficient iterative process for improving MHC class II binding predictions.
机译:CD4阳性T辅助细胞可控制特异性免疫的许多方面。这些细胞对衍生自蛋白质抗原的肽具有特异性,并由极其多态的主要组织相容性复合体(MHC)II类系统的分子呈递。因此,鉴定与II类MHC分子结合的肽对于合理发现免疫表位至关重要。 HLA-DR是人类MHC II类的一个突出例子。在这里,我们提出了一种NetMHCIIpan方法,该方法可以对与已知序列的任何HLA-DR分子结合的肽进行泛特异性预测。该方法源自大量的定量HLA-DR结合事件的汇编,这些事件涵盖了500多个已知的HLA-DR等位基因中的14个。考虑到肽和HLA序列信息,该方法还可以针对缺乏实验数据的HLA-DR分子进行概括和预测肽结合。该方法的验证包括鉴定内源性HLA II类配体,交叉验证,留下一个分子以及迄今未表征的HLA-DR分子的结合基序鉴定。验证表明,该方法可以成功预测HLA-DR分子的结合-即使在没有有关特定分子的特定数据的情况下。此外,与TEPITOPE(目前是旨在提供广泛的HLA-DR等位基因覆盖面的当前唯一的其他公开可用的预测方法)相比,NetMHCIIpan在TEPITOPE训练中包含的等位基因表现相同,而在新等位基因上却胜过TEPITOPE。我们建议该方法可用于识别那些迄今未表征的等位基因,应在该方法的未来更新中以实验方式解决,以最有效地覆盖HLA-DR的多态性。因此,我们得出的结论是,提出的方法面临着与MHC多态性发现率保持一致的挑战,并且可以用来对MHC“空间”进行采样,从而为改善MHC II类结合预测提供了高效的迭代过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号